ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "TNF-blocking Antibody"

  • Abstract Number: 0057 • ACR Convergence 2025

    TNF Inhibition with Small-molecule Agents Results in Amelioration of Inflammation Similar to that of Anti-TNF Biologics While Preserving TNFR2 Signaling and Maintaining a Suppressive Regulatory T cell Phenotype

    Rajesh Singh1, Bindi Patel2, Rameshwari Rayaji2, Archana Sidalaghatta Nagaraja2, Saranya Chandrasekar2, Yihong Guan2, Ritu Kushwaha2, Yue Tong Lee2, Cesar Meleza2, Matthew Epplin2, Brandon Rosen2, Manmohan R Leleti2, Matthew J Walters2 and Daniel DiRenzo2, 1Arcus Biosciences, inc., Santa Clara, CA, 2Arcus Biosciences, inc., Hayward, CA

    Background/Purpose: Anti-TNF biologics are effective in the treatment of inflammatory diseases such as rheumatoid arthritis and psoriasis. However, they can lead to de novo inflammation…
  • Abstract Number: 2676 • ACR Convergence 2025

    Tofacitinib in Juvenile spondyloarthropathy: clinical efficacy, impact on biomarkers and comparison with Adalimumab

    Anu Balakrishnan1, Asif Khan2, Shivika Guleria3, Fareha Umam4, Naveen R5, Priyansh Jain2, Lekshmi Minikumari Rahulan2, Rudrarpan Chatterjee6 and Amita Aggarwal7, 1Sanjay Gandhi Post Graduate Institute, India, Lucknow, Uttar Pradesh, India, 2Sanjay Gandhi Postgraduate Institute of Medical sciences Lucknow, Lucknow, Uttar Pradesh, India, 3SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, 4Dept of Clinical Immunology and Rheumatology, SGPGIMS, Lucknow, Uttar Pradesh, India, 5Sanjay Gandhi Post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, 6Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow., Lucknow, Uttar Pradesh, India, 7Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India

    Background/Purpose: Tofacitinib is a JAK inhibitor that has been approved for treatment of polyarticular Juvenile idiopathic arthritis. However, data on its use in juvenile spondyloarthropathy…
  • Abstract Number: 2543 • ACR Convergence 2025

    Severe Visual Impairment in Behçet Syndrome in Time: A Comparison of Four Time Periods

    Mustafa Erdogan1, Koray Tascilar2, Yagmur Ersoya3, Alp Ozcan4, Mert Gurcan4, Talal Ammar4, Sinem Nihal Esatoglu5, Yesim Ozguler5, Gulen Hatemi5 and Hasan Yazici6, 1Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Department of Internal Medicine, Division of Rheumatology / Marmara University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Friedrich Alexander University of Erlangen Nuremberg, Universitätsklinikum Erlangen Department of Medicine 3, Rheumatology and Immunology, Erlangen, Germany, 3Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Department of Internal Medicine, Istanbul, Turkey, 4Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey, 5Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 6Academic Hospital, Istanbul, Turkey

    Background/Purpose: There is consensus that the visual prognosis in Behçet syndrome (BS) uveitis has considerably improved in time (1-3). We wanted to better quantitate this…
  • Abstract Number: 2391 • ACR Convergence 2025

    Antinuclear Antibody Positivity in Patients with Psoriasis and Psoriatic Arthritis and the Risk of Developing Clinical Symptoms of SLE Following TNF Inhibitor Therapy

    Damira Sereda1, Leilani Leechalad1 and Andras Perl2, 1SUNY Upstate Medical University, Syracuse, NY, 2SUNY, Syracuse, NY

    Background/Purpose: It has been reported that the presence of positive ANA in patients treated with TNF inhibitors (TNFi) could be associated with the development of…
  • Abstract Number: 2360 • ACR Convergence 2025

    Treatment adherence in ankylosing spondylitis: A comparison of TNFi, IL-17i, and JAKi using real-world data

    Marina Magrey1 and Jennifer Murphy2, 1Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH, 2University Hospitals, Cleveland Medical Center, cleveland, OH

    Background/Purpose: Treatment adherence is essential for achieving sustained disease control and improving outcomes in patients with ankylosing spondylitis (AS). This study aimed to evaluate real-world…
  • Abstract Number: 2276 • ACR Convergence 2025

    Long-Term Cardiovascular Risk Following Tnfi vs Triple Therapy: A Post-hoc Analysis Integrating Randomized Clinical Trial and Electronic Health Record Data

    Jennifer Hanberg1, David Cheng2, Xuan Wang3, Rahul Sangar4, Yuk-Lam Ho4, Lauren Costa4, Rachael Matty4, Candace Feldman1, Tate Johnson5, Joshua Baker6, Bryant England5, J. Michael Gaziano1, Kelly Cho7, James O'Dell5, Grant Cannon8, Paul Monach4, Ted Mikuls5, Tianxi Cai7 and Katherine Liao1, 1Brigham and Women's Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, MA, 3University of Utah, Salt Lake City, UT, 4VA Boston Healthcare System, Boston, MA, 5University of Nebraska Medical Center, Omaha, NE, 6University of Pennsylvania, Philadelphia, PA, 7Harvard Medical School, Boston, MA, 8University of Utah and Salt Lake City VA, Salt Lake City, UT

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are often avoided when treating rheumatoid arthritis (RA) patients with decompensated heart failure (HF), based on increased rates of…
  • Abstract Number: 2274 • ACR Convergence 2025

    Importance Of Fc Region On Therapeutic Survival In Rheumatoid Arthritis Patients With Anti-TNF Therapy

    ELENA GRAU GARCIA1, Iago Alcántara Álvarez2, Jose Ivorra Cortes3, Pablo Muñoz Martinez4, Laura Mas Sanchez5, Alba Maria Torrat Noves6, Daniel Ramos Castro7, Belen Villanueva Manes8, Miguel Simeo Vinaixa4, Andres Perez Hurtado9 and José Andrés Román Ivorra10, 1HUP La Fe, Valencia, Comunidad Valenciana, Spain, 2Hospital Universitari i Politénic La Fe, València, Spain, 3Hospital Universitario La Fe, Valencia, Comunidad Valenciana, Spain, 4Rheumatology Department. HUP La Fe, Valencia, Spain, 5Hospital Universitari i Politecnic La Fe, València, Spain, 6Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, 7Hospital Universitari i Politecnic La Fe, Valencia, Spain, 8Hospital La Fe, València, Spain, 9Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, 10Hospital Universitari i Politècnic La Fe, Valencia, Spain

    Background/Purpose: In patients affected by rheumatoid arthritis (RA), it has been studied a relation between high rheumatoid factor (RF) and a favorable response to anti-TNF…
  • Abstract Number: 1702 • ACR Convergence 2025

    Powerful and Accurate Case-Control Analysis of Spatially Resolved Molecular Data in Autoimmune Disease

    Yakir Reshef1, Lakshay Sood1, Michelle Curtis1, Laurie Rumker2, DANIEL STEIN3, Mukta Palshikar1, Saba Nayar4, Andrew Filer5, Anna Helena Jonsson6, ilya Korsunsky7 and Soumya Raychaudhuri7, 1Brigham and Women's Hospital, Boston, 2Broad Institute, Boston, 3Harvard University, Boston, 4University of Birmingham, Birmingham, United Kingdom, 5The University of Birmingham, Birmingham, United Kingdom, 6University of Colorado School of Medicine, Aurora, CO, 7Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Autoimmune diseases such as rheumatoid arthritis (RA) involve complex spatial organization of immune and stromal cells within inflamed tissues. As spatial molecular profiling methods…
  • Abstract Number: 1615 • ACR Convergence 2025

    Prevalence of Clinical and Laboratory Manifestations of Patients with Deficiency of Adenosine Deaminase 2 (DADA2): A Systematic Review and Meta-Analysis

    Athanasios Vassilopoulos1, Stephanos Vassilopoulos1, Anushri Nimbvikar1, Eleftherios Mylonakis2 and Anthony M. Reginato3, 1Division of Internal Medicine, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island, Providence, 2Department of Medicine, Houston Methodist Hospital, Houston, 3Brown University, Providence, RI

    Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is a rare autosomal recessive autoinflammatory disorder first identified in 2014. Four major disease phenotypes have been described:…
  • Abstract Number: 1368 • ACR Convergence 2025

    Thrombocytosis Predicts Response to Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis: Data from the Korean KOBIO Registry

    Se Hee Kim1 and kyung-Ann Lee2, 1Kyung Hee University College of Medicine, Seoul, Republic of Korea, 2Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea

    Background/Purpose: This study aimed to evaluate the clinical characteristics of thrombocytosis, its relationship with disease activity and joint involvement, and its influence on the effectiveness…
  • Abstract Number: 1366 • ACR Convergence 2025

    Cost Per Responder Analysis of Certolizumab Pegol Versus Adalimumab in Patients with Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective from Canada and Brazil

    Rémi Marty1, Baran Ufuktepe2, Nicola Tilt3, Flore Decuypere4, Angela Blake3, Sandeep Kiri3 and Mohammed Soomro3, 1UCB Pharma, Brussels, Belgium, Anderlecht, Belgium, 2UCB Pharma Istanbul, Turkey, istanbul, Turkey, 3UCB Pharma, Slough, United Kingdom, Slough, United Kingdom, 4UCB Pharma Brussels, Belgium, Brussels, Belgium

    Background/Purpose: According to the 2022 EULAR recommendations for the management of rheumatoid arthritis (RA), the presence of rheumatoid factor (RF), particularly at high levels, is…
  • Abstract Number: 0416 • ACR Convergence 2025

    Outcomes Of Children with Juvenile Idiopathic Arthritis Receiving Biological Disease-Modifying Anti-Rheumatic Drugs: Retrospective Analysis of A Real-World Experience From A Resource-Limited Setting

    Narendra Bagri1, Pavneet Kaur2, Farheen KS2, Bala Siva rama Krishna J2, Banoth Sreesanth2, Ayisha KP2, Bareddy Sai Thrisha Reddy2, ASHISH DATT UPADHYAY2, RAKESH LODHA2 and Sushil Kumar kabra2, 1All India Institute of Medical Sciences(AIIMS), New Delhi, Delhi, India, 2All India Institute of Medical Sciences, New Delhi, India

    Background/Purpose: We aimed to study the outcomes (remission, flare, and adverse events) of biological disease-modifying anti-rheumatic drugs (bDMARD) in children with JIA from a low-middle-income…
  • Abstract Number: 0407 • ACR Convergence 2025

    The SOS project: to Switch Or to Swap After Adalimumab failure for the management of childhood non-infectious uveitis in an international cohort

    Ilaria Maccora1, Margaret Chang2, Sheila Angeles-Han3, Andrea Taddio4, Lampros Fotis5, Cinzia de Libero6, Madison Mangin7, Alexandra Duell8, Marco Gabrielli9, Kyveli Chiotopoulou5, Lillian Sutton10, Virginia Miraldi Utz8 and Gabriele Simonini11, 1Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy, Firenze, Florence, Italy, 2Boston Children's Hospital, Boston, MA, 3Cincinnati Children's Hospital, Cincinnati, OH, 4Insitute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy, 5Division of Pediatric Rheumatology, Department of Pediatrics, ATTIKON General Hospital, National and Kapodistrian University of Athens, Greece, Athene, Greece, 6Ophthalmology Unit, Meyer Children's Hospital IRCCS, Florence, Italy, Florence, Italy, 7Boston Children's Hospital, St Simons Island, GA, 8Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9University of Trieste, Trieste, Italy, Trieste, Italy, 10Division of Immunology, Boston Children’s Hospital, Boston, MA, USA, Boston, 11Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy

    Background/Purpose: Childhood chronic non-infectious uveitis (cNIU) is a sight-threatening condition that can lead to blindness if not appropriately treated. cNIU is typically associated with Juvenile…
  • Abstract Number: 0111 • ACR Convergence 2025

    Predicting Response To Adalimumab In Patients With Psoriatic Arthritis Using Epigenetic Chromosome Conformation Signatures

    Patricia Riedlova1, Ewan Hunter2, Christine Huppertz3, Maarten de Wit4, Stephen R. Pennington5, Oliver FitzGerald6, Jochen M. Schwenk7, Rik Lories8, Carl S. Goodyear1 and Stefan Siebert1, 1University of Glasgow, Glasgow, United Kingdom, 2Oxford BioDynamics Plc, Oxford, United Kingdom, 3Novartis Pharma AG, Basel, Switzerland, 4Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, 5University College Dublin, DUBLIN, Ireland, 6UCD, Dublin 6, Dublin, Ireland, 7KTH Royal Institute of Technology, Solna, Sweden, 8KU Leuven, Leuven, Belgium

    Background/Purpose: TNF inhibitors (TNFi) have proven efficacy in psoriatic arthritis (PsA) and are commonly prescribed as first line targeted therapy in PsA. However, response to…
  • Abstract Number: 0074 • ACR Convergence 2025

    Rheumatoid Factors (RFs) in RA Patient Sera Do Not Bind To Fc-Free Certolizumab Pegol, But Do Bind To Fc-Containing Anti-TNF-α Biological DMARDs, Driving Immune Complex Formation and Cellular Clearance

    Sophie Hopkin1, Kathryn Malpas1, David Kallenberg1, Jacqueline O'Neill1, Geofrey Odede1, Kerry Tyson1, Sue Cross1, Tatiana SOKOLOVA2, Bernard Lauwerys3, Baran Ufuktepe4, Patrick Durez5, Susanna Bidgood1 and David Humphreys1, 1UCB Pharma, Slough, England, United Kingdom, 2Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, 3Systemic and Inflammatory Rheumatic Diseases Section, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium, 4UCB Pharma Istanbul, Turkey, istanbul, Turkey, 5Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Brussels Hoofdstedelijk Gewest, Belgium

    Background/Purpose: RFs are polyclonal autoantibodies which bind the Fc domain of IgGs. Patients with RA and high RF levels experience reduced serum drug concentrations and…
  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology